Keryx Biopharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch KERX and buy or sell other stocks, ETFs, and their options commission-free!

About KERX

Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. 

CEO
Jodie P. Morrison
CEOJodie P. Morrison
Employees
Employees
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1998
Founded1998
Employees
Employees

KERX Key Statistics

Market cap
404.49M
Market cap404.49M
Price-Earnings ratio
-4.41
Price-Earnings ratio-4.41
Dividend yield
Dividend yield
Average volume
2.10M
Average volume2.10M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$5.98
52 Week high$5.98
52 Week low
$2.47
52 Week low$2.47

Stock Snapshot

With a market cap of 404.49M, Keryx Biopharmaceuticals(KERX) trades at $3.36. The stock has a price-to-earnings ratio of -4.41.

Keryx Biopharmaceuticals(KERX) stock opened on 2026-03-13 at —. The price climbed to — and dipped to —.

Keryx Biopharmaceuticals(KERX) shares are trading with a volume of 0, against a daily average of 2.1M.

In the last year, Keryx Biopharmaceuticals(KERX) shares hit a 52-week high of $5.98 and a 52-week low of $2.47.

In the last year, Keryx Biopharmaceuticals(KERX) shares hit a 52-week high of $5.98 and a 52-week low of $2.47.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.